CA2583336A1 - Use of nordihydroguaiaretic acid derivatives in the treatment of drug resistant cancer, viral and microbial infection - Google Patents

Use of nordihydroguaiaretic acid derivatives in the treatment of drug resistant cancer, viral and microbial infection Download PDF

Info

Publication number
CA2583336A1
CA2583336A1 CA002583336A CA2583336A CA2583336A1 CA 2583336 A1 CA2583336 A1 CA 2583336A1 CA 002583336 A CA002583336 A CA 002583336A CA 2583336 A CA2583336 A CA 2583336A CA 2583336 A1 CA2583336 A1 CA 2583336A1
Authority
CA
Canada
Prior art keywords
amino acid
acid residue
use according
residue
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002583336A
Other languages
English (en)
French (fr)
Inventor
David E. Mold
Yuan C. Lee
Chih-Chuan Chang
Ru Chih C. Huang
Jih-Ru Hwu
Ming-Hua Hsu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2583336A1 publication Critical patent/CA2583336A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002583336A 2004-10-06 2005-10-06 Use of nordihydroguaiaretic acid derivatives in the treatment of drug resistant cancer, viral and microbial infection Abandoned CA2583336A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61611404P 2004-10-06 2004-10-06
US60/616,114 2004-10-06
PCT/US2005/035795 WO2006041902A2 (en) 2004-10-06 2005-10-06 Use of nordihydroguaiaretic acid derivatives in the treatment of drug resistant cancer, viral and microbial infection

Publications (1)

Publication Number Publication Date
CA2583336A1 true CA2583336A1 (en) 2006-04-20

Family

ID=36148866

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002583336A Abandoned CA2583336A1 (en) 2004-10-06 2005-10-06 Use of nordihydroguaiaretic acid derivatives in the treatment of drug resistant cancer, viral and microbial infection

Country Status (8)

Country Link
US (1) US20080207532A1 (cg-RX-API-DMAC7.html)
EP (1) EP1848418A4 (cg-RX-API-DMAC7.html)
JP (1) JP2008520548A (cg-RX-API-DMAC7.html)
CN (1) CN101437505A (cg-RX-API-DMAC7.html)
AU (1) AU2005294432A1 (cg-RX-API-DMAC7.html)
CA (1) CA2583336A1 (cg-RX-API-DMAC7.html)
MX (1) MX2007004025A (cg-RX-API-DMAC7.html)
WO (1) WO2006041902A2 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8440800B2 (en) * 2006-08-28 2013-05-14 The Ohio State University Research Foundation Compositions for reducing cell adhesion to bubbles
US8178527B2 (en) * 2006-10-02 2012-05-15 Erimos Pharmaceuticals Llc Tetra-substituted NDGA derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use
RS53165B (sr) 2007-03-14 2014-06-30 Bionsil S.R.L. Inhibitori btk za lečenje epitelnih tumora rezistentnih na hemoterapijske lekove
US9149526B2 (en) 2008-01-08 2015-10-06 The Johns Hopkins University Suppression of cancer growth and metastasis using nordihydroguaiaretic acid derivatives with metabolic modulators
US20100093872A1 (en) * 2008-10-15 2010-04-15 Erimos Pharmaceuticals Llc Stable aqueous formulations of water insoluble or poorly soluble drugs
MX2011004824A (es) * 2008-11-07 2012-01-12 Triact Therapeutics Inc Uso de derivados de butano catecólico en terapia contra el cáncer.
ES2525833T3 (es) * 2010-02-22 2014-12-30 The Johns Hopkins University Supresión del crecimiento del cáncer y la metástasis mediante el uso de derivados de ácido nordihidroguayarético con 7-hidroxiestaurosporina
US10342767B2 (en) 2011-04-21 2019-07-09 Children's Hospital Medical Center Therapy for kinase-dependent malignancies
EP2699237A4 (en) * 2011-04-21 2014-11-12 Childrens Hosp Medical Center THERAPY FOR LEUKEMIA
WO2012166778A2 (en) * 2011-05-31 2012-12-06 The Johns Hopkins University Conjugates of nitroimidazoles and their use as chemotherapeutic agents
WO2013116821A1 (en) * 2012-02-03 2013-08-08 The Johns Hopkins University Compositions comprising ndga derivatives and sorafenib and their use in treatment of cancer
AU2014223548A1 (en) 2013-02-26 2015-10-15 Triact Therapeutics, Inc. Cancer therapy
GB201307989D0 (en) * 2013-05-02 2013-06-12 Helperby Therapeutics Ltd Novel combinations and use
WO2015035410A1 (en) 2013-09-09 2015-03-12 Triact Therapeutic, Inc. Cancer therapy
CN105902526A (zh) * 2016-05-06 2016-08-31 兰州大学 马索罗酚在制备治疗包虫病的药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0289506A4 (en) * 1986-11-19 1990-12-12 Chemex Pharmaceuticals, Inc. Lipoxygenase inhibitors
US5409690A (en) * 1993-06-23 1995-04-25 Chemex Pharmaceuticals, Inc. Treatment of multidrug resistant diseases in cancer cell by potentiating with masoprocol
US6214874B1 (en) * 1999-10-15 2001-04-10 John Hopkins University Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N
WO2006014669A2 (en) * 2004-07-20 2006-02-09 Erimos Pharmaceuticals Llc Methods and compositions for treatment of intraepithelial neoplasia

Also Published As

Publication number Publication date
CN101437505A (zh) 2009-05-20
MX2007004025A (es) 2007-06-11
WO2006041902A2 (en) 2006-04-20
EP1848418A2 (en) 2007-10-31
AU2005294432A1 (en) 2006-04-20
JP2008520548A (ja) 2008-06-19
US20080207532A1 (en) 2008-08-28
EP1848418A4 (en) 2010-09-08
WO2006041902A3 (en) 2009-04-16

Similar Documents

Publication Publication Date Title
US20080207532A1 (en) Use of Nordihydroguaiaretic Acid Derivatives in the Treatment of Drug Resistant Cancer, Viral and Microbial Infection
RU2767664C2 (ru) Комбинированная терапия противоопухолевым алкалоидом
JP5514123B2 (ja) 卵巣癌を治療するための、パクリタキセルを含む配合剤
JP5440985B2 (ja) メラノーマの治療
PT1439839E (pt) Associação compreendendo combretastatina e agentes anticancerígenos
Chang et al. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel
JP2019513812A (ja) 化学療法の改善
US20170112807A1 (en) Combination chemotherapy comprising a liposomal prodrug of mitomycin c
US20050288378A1 (en) Cancer chemotherapy
WO2019032769A1 (en) POLYTHERAPIES COMPRISING HDAC INHIBITORS AND TUBULIN INHIBITORS
US6562834B2 (en) Combination comprising camptothecin and a stilbene derivative for the treatment of cancer
TW202114682A (zh) Mcl-1抑制劑與乳癌標準療法之組合，其用途及醫藥組合物
JP7311177B2 (ja) Ａ－ＮＯＲ－５αアンドロスタン薬物と抗がん薬物との併用
HK1131740A (en) Use of nordihydroguaiaretic acid derivatives in the treatment of drug resistant cancer, viral and microbial infection
TWI827310B (zh) 異硫氰酸酯結構修飾化合物於預防或治療肝臟疾病之用途
JP2005239634A (ja) 乳ガン細胞増殖阻害剤

Legal Events

Date Code Title Description
FZDE Discontinued